The last decade was an eventful one for the Life Sciences industry. It saw a single product, Pfizer’s Lipitor, earn over $10 billion in a single year. While another blockbuster, Merck’s Vioxx, fell from grace after studies showed an increased rate of heart attacks and strokes in patients. Merck’s cholesterol-lowering drug ,Zocor,went off patent in 2006 and sales fell 65 percent in six months.1 The small molecule blockbuster drugs gave way to more complicated biotech products as companies came under increasing pressure from generic manufacturers. The industry was actively consolidating throughout the decade with several mega-mergers punctuating the end. Now as the new decade begins the next wave of challenges have already presented themselves.
Register now! to review the latest insight papers, case studies, articles, and research. Registration is free.
|
